Using PETMR Imaging to Evaluate and Stage Newly Diagnosed NKT-cell Lymphoma in Patients Aged 14 to 70

What this Trial Is About

Researchers are evaluating the use of Positron Emission TomographyMagnetic Resonance PETMR imaging to improve staging and treatment evaluation for patients newly diagnosed with NKT-cell lymphoma, a fast-growing and varied type of lymphoma that often affects the nasal area and other body sites. Current standard imaging methods are separate and can be inconvenient, so this study aims to explore a more accurate way to predict patient outcomes and guide therapy. This prospective, single-arm clinical study involves patients undergoing PETMR scans within 28 days before starting treatment. Depending on their cancer stage, patients receive follow-up PETMR scans after specific numbers of treatment cycles to assess mid-term and final treatment effects. After treatment, participants have regular follow-ups every 12 weeks for the first year and every 24 weeks thereafter, including clinical exams and additional imaging, to monitor disease status until progression, death, withdrawal, or study completion. Participants will undergo detailed assessments including PETMR scans, clinical symptom checks, physical exams, and enhanced CT and MR imaging of affected areas. The study will measure how well PETMR identifies disease stage and treatment response, aiming to develop a predictive system based on these imaging results. Safety monitoring includes histopathological confirmation if disease progression is suspected, with total involvement lasting up to about four years depending on each participants course.

PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma